US 11008314
Compounds and methods for modulating interleukin-2-inducible t-cell kinase
granted A61PA61P35/00A61P43/00
Quick answer
US patent 11008314 (Compounds and methods for modulating interleukin-2-inducible t-cell kinase) held by Corvus Pharmaceuticals, Inc. expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corvus Pharmaceuticals, Inc.
- Grant date
- Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61P, A61P35/00, A61P43/00